KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Revenue (2016 - 2025)

Pfizer (PFE) has disclosed Revenue for 17 consecutive years, with $17.6 billion as the latest value for Q4 2025.

  • Quarterly Revenue changed N/A to $17.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.2 billion through Dec 2025, up 68.59% year-over-year, with the annual reading at $62.6 billion for FY2025, 646.05% up from the prior year.
  • Revenue for Q4 2025 was $17.6 billion at Pfizer, up from $2.3 billion in the prior quarter.
  • The five-year high for Revenue was $27.7 billion in Q3 2022, with the low at $442.0 million in Q3 2024.
  • Average Revenue over 5 years is $12.7 billion, with a median of $13.7 billion recorded in 2025.
  • The sharpest move saw Revenue crashed 96.72% in 2024, then soared 419.91% in 2025.
  • Over 5 years, Revenue stood at $3.4 billion in 2021, then dropped by 4.65% to $3.3 billion in 2022, then grew by 5.31% to $3.4 billion in 2023, then tumbled by 87.13% to $442.0 million in 2024, then soared by 3872.17% to $17.6 billion in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $17.6 billion, $2.3 billion, and $14.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.